Morbidity and quality of life following cytoreduction and HIPEC

Research output: Chapter in Book/Report/Conference proceedingChapter


The evolution of locoregional therapy in the last 2 decades has changed the perpective in the clinical management of patients affected by peritoneal surface malignancies from mere palliation to possible cure [1]. Results from Phase II studies testing the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemoperfusion (HIPEC) in the treatment of peritoneal carcinomatosis (PC) of various origins have been encouraging [2]. In previous papers, we reported 5-year overall survival rates of 97% and 57%, respectively, for patients with pseudomyxoma peritonei [3] and malignant peritoneal mesothelioma [4-5] treated with CRS and HIPEC. Other authors have reported 5-year overall survival rates of 63.4% and 19%, respectively, in ovarian [6] and colorectal cancer [7]. Moreover, results of a phase III trial have confirmed the superiority of CRS and HIPEC in the treatment of patients with PC from colorectal cancer over other standard surgical and/or systemic chemotherapy (CT) modalities [8].

Original languageEnglish
Title of host publicationPeritoneal Carcinomatosis: A Multidisciplinary Approach
PublisherSpringer US
Number of pages16
ISBN (Print)0387489916, 9780387489919
Publication statusPublished - 2007

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Morbidity and quality of life following cytoreduction and HIPEC'. Together they form a unique fingerprint.

Cite this